Carbamazepine (All indications) updated on 04-22-2025

Preeclampsia

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9602
R34036		 Aydin (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 Preeclampsia/ eclampsia throughout pregnancy retrospective cohort exposed to other treatment, sick excluded Adjustment: No 0.45 [0.01;25.16] C
excluded (control group) 		0/15   0/7 0 15
ref
S9603
R34046		 Aydin (Carbamazepine) (Controls unexposed, sick), 2020 Preeclampsia/ eclampsia throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 1.48 [0.03;79.05] C 0/15   0/22 0 15
ref
S9761
R34850		 Cohen (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 Preeclampsia early pregnancy retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 0.96 [0.61;1.52]
excluded (control group) 		78/1,232   129/2,682 207 1,232
ref
S9762
R34857		 Cohen (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019 Preeclampsia early pregnancy retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.29 [0.94;1.77] 78/1,232   53,634/1,440,631 53,712 1,232
ref
S9752
R34821		 Borthen (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2011 Pre-eclampsia during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick excluded Adjustment: No 0.31 [0.06;1.67] C
excluded (control group) 		2/28   6/30 8 28
ref
S9754
R34829		 Borthen (Carbamazepine) (Controls unexposed, disease free), 2011 Pre-eclampsia during pregnancy (anytime or not specified) retrospective cohort unexposed, disease free excluded Adjustment: No Matched 1.40 [0.30;6.50]
excluded (control group) 		2/28   11/205 13 28
ref
S9756
R34837		 Borthen (Carbamazepine) (Controls unexposed, sick), 2011 Pre-eclampsia during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 0.55 [0.11;2.62] C 2/28   11/89 13 28
ref
Total 3 studies 1.25 [0.92;1.70] 53,725 1,275
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Aydin (Carbamazepine) (Controls unexposed, sick), 2020Aydin, 2020 1 1.48[0.03; 79.05]0151%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Cohen (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019Cohen, 2019 2 1.29[0.94; 1.77]53,7121,23296%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Borthen (Carbamazepine) (Controls unexposed, sick), 2011Borthen, 2011 3 0.55[0.11; 2.62]13284%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 0% 1.25[0.92; 1.70]53,7251,2750.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine) (Controls unexposed, sick; 2: Carbamazepine) (Controls unexposed NOS) (Mixed indications; 3: Carbamazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.25[0.92; 1.70]53,7251,2750%NAAydin (Carbamazepine) (Controls unexposed, sick), 2020 Cohen (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019 Borthen (Carbamazepine) (Controls unexposed, sick), 2011 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.29[0.94; 1.77]53,7121,232 -NACohen (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019 1 unexposed, sickunexposed, sick 0.62[0.14; 2.69]13430%NAAydin (Carbamazepine) (Controls unexposed, sick), 2020 Borthen (Carbamazepine) (Controls unexposed, sick), 2011 2 Tags Adjustment   - No  - No 0.62[0.14; 2.69]13430%NAAydin (Carbamazepine) (Controls unexposed, sick), 2020 Borthen (Carbamazepine) (Controls unexposed, sick), 2011 2   - Yes  - Yes 1.29[0.94; 1.77]53,7121,232 -NACohen (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019 1 All studiesAll studies 1.25[0.92; 1.70]53,7251,2750%NAAydin (Carbamazepine) (Controls unexposed, sick), 2020 Cohen (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019 Borthen (Carbamazepine) (Controls unexposed, sick), 2011 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9752, 9754, 9761, 9602

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.29[0.95; 1.76]53,7251,2600%NACohen (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019 Borthen (Carbamazepine) (Controls unexposed, disease free), 2011 2 unexposed, sick controlsunexposed, sick controls 0.62[0.14; 2.69]13430%NAAydin (Carbamazepine) (Controls unexposed, sick), 2020 Borthen (Carbamazepine) (Controls unexposed, sick), 2011 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.88[0.57; 1.37]2151,2750%NAAydin (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 Cohen (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 Borthen (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2011 30.510.01.0